Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin

Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives. To determine the effects of omal...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Theranostics
Main Authors: Metz, Martin, Staubach, Petra, Bauer, Andrea, Brehler, Randolf, Gericke, Janine, Kangas, Michael, Ashton-Chess, Joanna, Jarvis, Philip, Georgiou, Panayiotis, Canvin, Janice, Hillenbrand, Rainer, Erpenbeck, Veit J., Maurer, Marcus
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2017
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5399592/
https://ncbi.nlm.nih.gov/pubmed/28435464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.18304
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki